Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-258 270 HEK-293 TNFSF-14 TR-2
- Product Overview:
LIGHT, also known as CD258, is a type II transmembrane glycoprotein encoded by TNFSF14 in humans.{61299} Alternative splicing of the TNFSF14 pre-mRNA produces a cytosolic isoform, as well as a membrane-bound isoform, which can be proteolytically cleaved by metalloproteinases to produce a soluble form.{62077,62078} It exists as a homotrimer and is constitutively expressed on immature dendritic cells and transiently expressed on activated T cells.{62078,61299} LIGHT is also expressed by other hematopoietic cells, including natural killer (NK) cells, monocytes, and granulocytes.{61300,62077} It binds to herpes virus entry mediator (HVEM) (Item No. 31840), also known as CD270, as well as the lymphotoxin ? receptor (LT?R), where it acts as a costimulatory molecule for T, B, and dendritic cells by promoting cytokine secretion, leading to cell differentiation and activation.{62077,61301} Tnfsf14-/- mice have increased mortality in a model of experimental autoimmune encephalitis (EAE), whereas Tnfsf14-/- mice have reduced inflammation in a model of graft versus host disease (GVHD), indicating additional roles in immune regulation.{62079,61299} Cayman’s LIGHT/CD258 Extracellular Domain (human, recombinant) protein can be used for enzyme activity assays. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of LIGHT/CD258 (amino acids 74-240) fused to human IgG1 Fc at its N-terminus, consists of 404 amino acids, and has a calculated molecular weight of 44.9 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.